MAGEA3 and melanoma: A phase 2 clinical study (NCT01266603) proved the safety profile of the combination therapy similar to that of high dose IL‐2 monotherapy and showed that vaccination provided strong anti‐tumor activity in melanoma patients.[141] The clinical immune monitoring data suggested a potential treatment strategy by combining MAGE‐A3+AS15 vaccine and ICIs.